In Europe, cardiovascular disease (CVD) represents the main cause of morbidity and mortality, costing countries € 190 billion yearly (2006). CVD prevention remains unsatisfactory across Europe largely due to poor control of CVD risk factors (RFs), growing incidence of obesity and diabetes, and sedentary lifestyle/poor dietary habits. Hypercholesterolaemia is a proven CVD RF, and LDL-C lowering slows atherosclerotic progression and reduces major coronary events. Lipid-lowering therapy is cost-effective, and intensive treatment of high-risk patients further improves cost effectiveness. In Italy, models indicate that improved cholesterol management translates into potential yearly savings of € 2.9-4 billion. Identifying and eliminating legislative and administrative barriers is essential to providing optimal lipid care to high-risk patients. Public health and government policy can influence clinical practice rapidly, and guideline endorsement via national health policy may reduce the CVD burden and change physician and patient behaviour. Action to reduce CVD burden should ideally include the integration of strategies to lower the incidence of major CV events, improvement in total CV risk estimation, database monitoring of CVD trends, and development of population educational initiatives on CVD prevention. Failure to bridge the gap between science and health policy, particularly in relation to lipid management, could result in missed opportunities to reverse the burgeoning epidemic of CVD in Europe

Atella, V., Brady, A., Catapano, A.L., Critchley, J., Graham, I.M., Hobbs, F., et al. (2009). Bridging science and health policy in cardiovascular disease: focus on lipid management: a report from a Session held during the 7th International symposium on multiple risk factors in cardiovascular diseases: prevention and intervention - health policy, in Venice, Italy, on 25 October, 2008. ATHEROSCLEROSIS SUPPLEMENTS, 10(1), 3-21 [10.1016/S1567-5688(09)70003-0].

Bridging science and health policy in cardiovascular disease: focus on lipid management: a report from a Session held during the 7th International symposium on multiple risk factors in cardiovascular diseases: prevention and intervention - health policy, in Venice, Italy, on 25 October, 2008

ATELLA, VINCENZO;
2009

Abstract

In Europe, cardiovascular disease (CVD) represents the main cause of morbidity and mortality, costing countries € 190 billion yearly (2006). CVD prevention remains unsatisfactory across Europe largely due to poor control of CVD risk factors (RFs), growing incidence of obesity and diabetes, and sedentary lifestyle/poor dietary habits. Hypercholesterolaemia is a proven CVD RF, and LDL-C lowering slows atherosclerotic progression and reduces major coronary events. Lipid-lowering therapy is cost-effective, and intensive treatment of high-risk patients further improves cost effectiveness. In Italy, models indicate that improved cholesterol management translates into potential yearly savings of € 2.9-4 billion. Identifying and eliminating legislative and administrative barriers is essential to providing optimal lipid care to high-risk patients. Public health and government policy can influence clinical practice rapidly, and guideline endorsement via national health policy may reduce the CVD burden and change physician and patient behaviour. Action to reduce CVD burden should ideally include the integration of strategies to lower the incidence of major CV events, improvement in total CV risk estimation, database monitoring of CVD trends, and development of population educational initiatives on CVD prevention. Failure to bridge the gap between science and health policy, particularly in relation to lipid management, could result in missed opportunities to reverse the burgeoning epidemic of CVD in Europe
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore SECS-P/02 - Politica Economica
English
Con Impact Factor ISI
cardiovascular disease; cholesterol; economics; government; health policy; LDL-C; public health; risk factors; acetylsalicylic acid; antilipemic agent; atorvastatin; beta adrenergic receptor blocking agent; cholesterol; dipeptidyl carboxypeptidase inhibitor; ezetimibe; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; pravastatin; rosuvastatin; simvastatin; acute coronary syndrome; article; atherosclerotic cardiovascular disease; cardiovascular disease; cardiovascular risk; clinical practice; clinical trial; cost control; cost effectiveness analysis; diabetes mellitus; dietary intake; disease course; drug mechanism; drug megadose; health care cost; health care policy; health education; heart infarction; high risk patient; high risk population; human; hypercholesterolemia; ischemic heart disease; lifestyle; morbidity; mortality; obesity; patient attitude; patient compliance; physician attitude; practice guideline; primary prevention; priority journal; quality adjusted life year; recurrent disease; risk reduction; antilipemic agents; cardiovascular diseases; cost of illness; Europe; government; health policy; humans; hydroxymethylglutaryl-CoA reductase inhibitors; lipid metabolism; preventive medicine; public health; risk factors; science; world health
Atella, V., Brady, A., Catapano, A.L., Critchley, J., Graham, I.M., Hobbs, F., et al. (2009). Bridging science and health policy in cardiovascular disease: focus on lipid management: a report from a Session held during the 7th International symposium on multiple risk factors in cardiovascular diseases: prevention and intervention - health policy, in Venice, Italy, on 25 October, 2008. ATHEROSCLEROSIS SUPPLEMENTS, 10(1), 3-21 [10.1016/S1567-5688(09)70003-0].
Atella, V; Brady, A; Catapano, A; Critchley, J; Graham, I; Hobbs, F; Leal, J; Lindgren, P; Vanuzzo, D; Volpe, M; Wood, D; Paoletti, R
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/48569
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact